Empiric therapy in lower respiratory tract infection - An ongoing challenge

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 3, 1997, Pages 5-9

  Geddes, A M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Acute exacerbations of chronic bronchitis; Atypical pneumonia; Community acquired pneumonia; Pneumonia

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEPHALOSPORIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; MACROLIDE; PENICILLIN G; QUINOLONE; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE;

AGING; ANTIBIOTIC RESISTANCE; CHRONIC BRONCHITIS; CHRONIC DISEASE; CONFERENCE PAPER; DISEASE SEVERITY; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNE DEFICIENCY; LOWER RESPIRATORY TRACT INFECTION; MEDICAL PRACTICE; MORBIDITY; MORTALITY; MYCOPLASMA PNEUMONIA; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 0030835423     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (22)

1. Evans GM, Gaisford WF. Treatment of pneumonia with 2-(p-aminobenzenesulphonamide) pyridine. Lancet 1938; 2: 14-19.
2. Tang CM, MacFarlane J. Early management of younger patients dying of community-acquired pneumonia. Respir Med 1993; 87: 289-294.
3. MacFarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society Study. Semin Respir Infect 1994; 9: 153-165.
4. Grüneberg RN. The Alexander Project: using in-vitro susceptibility data for choosing empirical therapy in LRTI. J Antimicrob Chemother 1996; 38 (Suppl A): 155-170.
5. Grüneberg RN, Felmingham D and the Alexander Project Group. Results of the Alexander Project: A continuing, multicentcr study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25: 169-181.
6. Woodhead MA. Management of pneumonia. Respir Med 1992; 86 (Suppl 6): 459-469.
7. Finch RG. Pneumonia: the impact of antibiotic resistance on its management. Microbial Drug Resistance 1995; 1: 149-158.
8. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991; 115 (Suppl 6): 428-436.
9. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. Quart J Med 1995; 88 (Suppl 1): 61-68.
10. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108 (Suppl 2): 43-52.
11. Allegra L, Grassi C, Grossi E et al. Ruolo degli antibiotica nel traitamento delle riacutizza della bronchite cronica. Ital J Chest Dis 1991; 45: 138-148.
12. Behler PG, Boge K, Bohning W, Gams W, Gartner- Toth M, Wettengel R. Amoxycillin/clavulanic acid vs cefetamet pivoxil in the treatment of acute exacerbation of chronic bronchitis (AECB) in adults. J Chemother 1995; 7 (Suppl 1): 16-20.
13. Cazzola M, Vinciguerra A, Beghi GF et al. Comparative evaluation of the clinical and microbiological efficacy of coamoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 1995; 7: 432-441.
14. Leigh DA, Fraser S, Hannington J, Ellison C. Multicentre randomised trial comparing the efficacy and tolerance of cefpodoxime proxetil 200 mg bid and Augmentin 750 mg tid in the treatment of acute exacerbations of chronic bronchitis. Abstract 1682, Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, California, 1992.
15. Lieberman D, Schlaeffer E. Once a day cefixime versus co-amoxiclav three times daily in the treatment of lower respiratory infections. J Antimicrob Chemother 1995; 35: 354-357.
16. O'Donovan C, Rudd R, O'Neill S et al. Augmentin (intravenous then oral) compared with cefuroxime followed by cephalexin for chest infections in hospitalised patients. Br J Clin Pract 1987; 41: 1044-1052.
17. Periti P, Novelli A, Schildwachter G, Schmidt Gayk H, Ryo Y, Zuck P. Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26 (Suppl E): 63-69.
18. Allegra L, Koneitzko N, Leophonte P et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother 1996; 37 (Suppl A): 93-104.
19. Barash M, Khan F, Clark R, Heyd A, Seligman M. Efficacy and safety of oral ciprofloxacin versus amoxycillin/clavulanate in the treatment of lower respiratory tract infections in adults. Eur J Clin Microbiol Infect Dis 1991; 10 (Suppl): 8-10.
20. Khajotia R, Drlicek M, Vetter N. Comparative study of ofloxacin and amoxycillin/clavulanate in hospitalised patients with lower respiratory tract infections. J Antimicrob Chemother 1990; 26 (Suppl D): 83-91.
21. Rademaker CMA, Sips AP, Beumer HM et al. A double-blind comparison of low-dose ofloxacin and amoxycillin/clavulanic acid in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1990; 26 (Suppl D): 75-81.
22. Beghi G, Berni F, Carratù L et al. Efficacy and tolerability of azithromycin versus amoxycillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 1995; 7: 146-152.